This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsReNeuron Group (RENE) 주식 개요Researches, develops, and commercializes cell-based therapies in the United Kingdom. 자세히 보기RENE 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장0/6과거 실적0/6재무 건전성4/6배당0/6강점지난 5년 동안 수입이 매년 17.8% 증가했습니다.위험 분석cash runway 경력이 1년 미만입니다.주식은 유동성이 매우 낮습니다수익이 USD$1m 미만입니다(£249K)의미 있는 시가총액이 없습니다(£2M)모든 위험 점검 보기RENE Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUK£Current PriceUK£0.0348.3k% 고평가 내재 할인율Est. Revenue$PastFuture-17m6m2016201920222025202620282031Revenue UK£6.6kEarnings UK£1.2kAdvancedSet Fair ValueView all narrativesReNeuron Group plc 경쟁사ProBiotix HealthSymbol: OFEX:PBXMarket cap: UK£12.5mAptamer GroupSymbol: AIM:APTAMarket cap: UK£19.9mRoquefort TherapeuticsSymbol: LSE:ROQMarket cap: UK£15.6mTheracryfSymbol: AIM:TCFMarket cap: UK£4.9m가격 이력 및 성과ReNeuron Group 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가UK£0.03452주 최고가UK£0.1152주 최저가UK£0.033베타0.691개월 변동0%3개월 변동-2.17%1년 변동-58.59%3년 변동-97.71%5년 변동-98.75%IPO 이후 변동-99.87%최근 뉴스 및 업데이트공시 • Aug 31ReNeuron Group Admission to Trading on AIM to Be Cancelled with Effect from 2 September 2024ReNeuron Group plc notified of the cancellation of the Company's ordinary shares ("Ordinary Shares") from trading on AIM. Further to the announcement on 2 August 2024 (the "Announcement"), Stephen Cork and Mark Smith of Cork Gully LLP (the "Joint Administrators"), have remained in discussions with the ReNeuron's main creditors to seek to clarify the liabilities of the Company and ascertain the Company's financial solvency in light of its current cash resources. The Joint Administrators anticipate being able to resolve matters such that the Company can exit Administration on a going concern basis in due course. However, this will only occur when the necessary legal documentation has been agreed and the Joint Administrators are working with creditors on this basis. In light of the above, as the Joint Administrators and the Board of ReNeuron no longer consider that there is a realistic possibility that the Company could raise sufficient funds to enable the Company to exit the Administration Process with sufficient working capital that would permit the restoration of trading on AIM on acceptable terms, notwithstanding the ongoing creditor discussions. Therefore,pursuant to Rule 41 of the AIM Rules, and with the ordinary shares of the Company having been suspended for more than six months, the Company's admission to trading on AIM will be cancelled with effect from 7.00 a.m. on 2 September 2024 ("Cancellation").공시 • Apr 17ReNeuron Group plc Announces Resignation of John Hawkins as Chief Financial Officer, Effect from 7 May 2024ReNeuron Group plc announced that John Hawkins will be stepping down as Chief Financial Officer of the Company with effect from 7 May 2024, in order to pursue other opportunities. Notwithstanding his departure, John will continue to provide support to the Company during the ongoing administration process.공시 • Jan 30ReNeuron Group plc Provides Group Earnings Guidance for the Second Half and Full Year 2024ReNeuron Group plc provided group earnings guidance for the second half and full year 2024. The Board continues to expect the Group to deliver a stronger performance in the second half than the first.Albeit the weaker regional economic environment means that the Group expects to deliver full year results below market expectations.Major Estimate Revision • Nov 28Consensus revenue estimates decrease by 28%, EPS upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from UK£910.0k to UK£650.0k. EPS estimate increased from -UK£0.105 to -UK£0.091 per share. Biotechs industry in the United Kingdom expected to see average net income growth of 25% next year. Consensus price target of UK£0.55 unchanged from last update. Share price rose 17% to UK£0.043 over the past week.New Risk • Nov 09New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: UK£5.1m Forecast net loss in 1 year: UK£1.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£5.3m free cash flow). Revenue is less than US$1m (UK£249k revenue, or US$306k). Market cap is less than US$10m (UK£3.05m market cap, or US$3.74m). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£1.4m net loss next year). Share price has been volatile over the past 3 months (7.7% average weekly change).공시 • Oct 27ReNeuron Group plc to Report First Half, 2024 Results on Nov 09, 2023ReNeuron Group plc announced that they will report first half, 2024 results on Nov 09, 2023더 많은 업데이트 보기Recent updates공시 • Aug 31ReNeuron Group Admission to Trading on AIM to Be Cancelled with Effect from 2 September 2024ReNeuron Group plc notified of the cancellation of the Company's ordinary shares ("Ordinary Shares") from trading on AIM. Further to the announcement on 2 August 2024 (the "Announcement"), Stephen Cork and Mark Smith of Cork Gully LLP (the "Joint Administrators"), have remained in discussions with the ReNeuron's main creditors to seek to clarify the liabilities of the Company and ascertain the Company's financial solvency in light of its current cash resources. The Joint Administrators anticipate being able to resolve matters such that the Company can exit Administration on a going concern basis in due course. However, this will only occur when the necessary legal documentation has been agreed and the Joint Administrators are working with creditors on this basis. In light of the above, as the Joint Administrators and the Board of ReNeuron no longer consider that there is a realistic possibility that the Company could raise sufficient funds to enable the Company to exit the Administration Process with sufficient working capital that would permit the restoration of trading on AIM on acceptable terms, notwithstanding the ongoing creditor discussions. Therefore,pursuant to Rule 41 of the AIM Rules, and with the ordinary shares of the Company having been suspended for more than six months, the Company's admission to trading on AIM will be cancelled with effect from 7.00 a.m. on 2 September 2024 ("Cancellation").공시 • Apr 17ReNeuron Group plc Announces Resignation of John Hawkins as Chief Financial Officer, Effect from 7 May 2024ReNeuron Group plc announced that John Hawkins will be stepping down as Chief Financial Officer of the Company with effect from 7 May 2024, in order to pursue other opportunities. Notwithstanding his departure, John will continue to provide support to the Company during the ongoing administration process.공시 • Jan 30ReNeuron Group plc Provides Group Earnings Guidance for the Second Half and Full Year 2024ReNeuron Group plc provided group earnings guidance for the second half and full year 2024. The Board continues to expect the Group to deliver a stronger performance in the second half than the first.Albeit the weaker regional economic environment means that the Group expects to deliver full year results below market expectations.Major Estimate Revision • Nov 28Consensus revenue estimates decrease by 28%, EPS upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from UK£910.0k to UK£650.0k. EPS estimate increased from -UK£0.105 to -UK£0.091 per share. Biotechs industry in the United Kingdom expected to see average net income growth of 25% next year. Consensus price target of UK£0.55 unchanged from last update. Share price rose 17% to UK£0.043 over the past week.New Risk • Nov 09New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: UK£5.1m Forecast net loss in 1 year: UK£1.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£5.3m free cash flow). Revenue is less than US$1m (UK£249k revenue, or US$306k). Market cap is less than US$10m (UK£3.05m market cap, or US$3.74m). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£1.4m net loss next year). Share price has been volatile over the past 3 months (7.7% average weekly change).공시 • Oct 27ReNeuron Group plc to Report First Half, 2024 Results on Nov 09, 2023ReNeuron Group plc announced that they will report first half, 2024 results on Nov 09, 2023공시 • Jul 25ReNeuron Group plc, Annual General Meeting, Aug 22, 2023ReNeuron Group plc, Annual General Meeting, Aug 22, 2023, at 08:30 Coordinated Universal Time. Location: at the offices of Covington & Burling LLP, Level 54, 22 Bishopsgate London United KingdomMajor Estimate Revision • Jun 01Consensus EPS estimates upgraded to UK£0.10 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -UK£0.14 to -UK£0.105 per share. Revenue forecast unchanged from UK£906.0k at last update. Biotechs industry in the United Kingdom expected to see average net income growth of 18% next year. Consensus price target down from UK£0.72 to UK£0.59. Share price fell 15% to UK£0.058 over the past week.Reported Earnings • May 26Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2023 results: UK£0.095 loss per share (improved from UK£0.17 loss in FY 2022). Net loss: UK£5.41m (loss narrowed 44% from FY 2022). Revenue missed analyst estimates by 20%. Earnings per share (EPS) exceeded analyst estimates by 21%.공시 • May 19ReNeuron Group plc to Report Q4, 2023 Results on May 25, 2023ReNeuron Group plc announced that they will report Q4, 2023 results on May 25, 2023Board Change • Apr 20High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Independent Non-Executive Director Mike Owen is the most experienced director on the board, commencing their role in 2015. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.공시 • Jan 04+ 1 more updateReNeuron Group plc Appoints Iain Ross as Executive ChairmanReNeuron Group plc announced that Iain Ross, who has been on the Board since July 2021, has been appointed as Executive Chairman and will lead a restructuring of the business, with further announcements to be made in due course. He is an experienced industry executive who has led several successful biotech turnarounds, including more recently that of Redx Pharma plc and Silence Therapeutics plc.Major Estimate Revision • Dec 09Consensus forecasts updatedThe consensus outlook for 2023 has been updated. 2023 losses forecast to reduce from -UK£0.17 to -UK£0.13 per share. Revenue forecast unchanged from UK£685.3k at last update. Biotechs industry in the United Kingdom expected to see average net income growth of 1.6% next year. Consensus price target of UK£0.79 unchanged from last update. Share price fell 27% to UK£0.11 over the past week.Reported Earnings • Dec 03First half 2023 earnings released: UK£0.056 loss per share (vs UK£0.092 loss in 1H 2022)First half 2023 results: UK£0.056 loss per share (improved from UK£0.092 loss in 1H 2022). Net loss: UK£3.18m (loss narrowed 39% from 1H 2022). Revenue is forecast to grow 5.2% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.Breakeven Date Change • Nov 16No longer forecast to breakevenThe 3 analysts covering ReNeuron Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of UK£22.8m in 2024. New consensus forecast suggests the company will make a loss of UK£10.3m in 2024.Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 independent directors. 4 non-independent directors. Senior Independent Non-Executive Director Barbara Staehelin was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Board Change • Sep 20Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 independent directors. 4 non-independent directors. Senior Independent Non-Executive Director Barbara Staehelin was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Reported Earnings • Aug 18Full year 2022 earnings released: UK£0.17 loss per share (vs UK£0.29 loss in FY 2021)Full year 2022 results: UK£0.17 loss per share (up from UK£0.29 loss in FY 2021). Net loss: UK£9.69m (loss narrowed 15% from FY 2021). Over the next year, revenue is forecast to grow 70%, compared to a 10% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.분석 기사 • Jul 15We Think ReNeuron Group (LON:RENE) Needs To Drive Business Growth CarefullyWe can readily understand why investors are attracted to unprofitable companies. For example, although...Price Target Changed • Jul 06Price target decreased to UK£2.22Down from UK£3.58, the current price target is provided by 1 analyst. New target price is 626% above last closing price of UK£0.30. Stock is down 72% over the past year. The company posted a net loss per share of UK£0.17 last year.Reported Earnings • Jul 04Full year 2022 earnings released: UK£0.17 loss per share (vs UK£0.29 loss in FY 2021)Full year 2022 results: UK£0.17 loss per share (up from UK£0.29 loss in FY 2021). Net loss: UK£9.69m (loss narrowed 15% from FY 2021). Over the next year, revenue is forecast to grow 53,796%, compared to a 160% growth forecast for the pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.Price Target Changed • Jun 16Price target decreased to UK£2.19Down from UK£3.79, the current price target is an average from 3 analysts. New target price is 584% above last closing price of UK£0.32. Stock is down 73% over the past year. The company posted a net loss per share of UK£0.29 last year.Price Target Changed • Apr 27Price target decreased to UK£2.04Down from UK£3.02, the current price target is an average from 2 analysts. New target price is 459% above last closing price of UK£0.36. Stock is down 75% over the past year. The company posted a net loss per share of UK£0.29 last year.분석 기사 • Jan 22We're Keeping An Eye On ReNeuron Group's (LON:RENE) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although...Price Target Changed • Jan 19Price target decreased to UK£2.04Down from UK£3.00, the current price target is an average from 2 analysts. New target price is 410% above last closing price of UK£0.40. Stock is down 68% over the past year. The company posted a net loss per share of UK£0.29 last year.Reported Earnings • Dec 02First half 2022 earnings: EPS and revenues miss analyst expectationsFirst half 2022 results: UK£0.092 loss per share (up from UK£0.22 loss in 1H 2021). Net loss: UK£5.23m (loss narrowed 26% from 1H 2021). Revenue missed analyst estimates by 48%. Earnings per share (EPS) also missed analyst estimates by 12%. Earnings per share (EPS) missed analyst estimates by 12%. Over the next year, revenue is forecast to grow 55%, compared to a 17% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 20% per year.분석 기사 • Oct 12Companies Like ReNeuron Group (LON:RENE) Can Afford To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Reported Earnings • Aug 22Full year 2021 earnings released: UK£0.29 loss per share (vs UK£0.36 loss in FY 2020)Full year 2021 results: Net loss: UK£11.3m (flat on FY 2020). Products in clinical trials Phase II: 2 Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.Reported Earnings • Jul 09Full year 2021 earnings released: UK£0.29 loss per share (vs UK£0.36 loss in FY 2020)Full year 2021 results: Net loss: UK£11.3m (flat on FY 2020). Products in clinical trials Phase II: 2 Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.분석 기사 • Jun 04Will ReNeuron Group (LON:RENE) Spend Its Cash Wisely?We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...분석 기사 • Jan 12Is ReNeuron Group (LON:RENE) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, although...Is New 90 Day High Low • Jan 07New 90-day high: UK£1.11The company is up 18% from its price of UK£0.94 on 09 October 2020. The British market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 10.0% over the same period.Is New 90 Day High Low • Dec 16New 90-day low: UK£0.72The company is down 15% from its price of UK£0.85 on 16 September 2020. The British market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period.Reported Earnings • Nov 26First half 2021 earnings released: UK£0.22 loss per shareFirst half 2021 results: Net loss: UK£7.09m (loss widened 82% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Nov 24New 90-day low: UK£0.78The company is down 23% from its price of UK£1.01 on 26 August 2020. The British market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.분석 기사 • Nov 20Here's What We Learned About The CEO Pay At ReNeuron Group plc (LON:RENE)Olav Hellebo has been the CEO of ReNeuron Group plc (LON:RENE) since 2014, and this article will examine the...주주 수익률RENEGB BiotechsGB 시장7D0%1.4%2.5%1Y-58.6%26.9%19.4%전체 주주 수익률 보기수익률 대 산업: RENE은 지난 1년 동안 26.9%의 수익을 기록한 UK Biotechs 산업보다 저조한 성과를 냈습니다.수익률 대 시장: RENE은 지난 1년 동안 19.4%를 기록한 UK 시장보다 저조한 성과를 냈습니다.주가 변동성Is RENE's price volatile compared to industry and market?RENE volatilityRENE Average Weekly Movementn/aBiotechs Industry Average Movement9.4%Market Average Movement5.7%10% most volatile stocks in GB Market12.0%10% least volatile stocks in GB Market3.0%안정적인 주가: RENE는 지난 3개월 동안 UK 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: Insufficient data to determine RENE의 변동성 변화를 판단할 수 없습니다.회사 소개설립직원 수CEO웹사이트199726n/awww.reneuron.com더 보기ReNeuron Group plc 기초 지표 요약ReNeuron Group의 순이익과 매출은 시가총액과 어떻게 비교됩니까?RENE 기초 통계시가총액UK£1.93m순이익 (TTM)-UK£5.07m매출 (TTM)UK£249.00k7.7x주가매출비율(P/S)-0.4x주가수익비율(P/E)RENE는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표RENE 손익계산서 (TTM)매출UK£249.00k매출원가UK£3.65m총이익-UK£3.40m기타 비용UK£1.67m순이익-UK£5.07m최근 보고된 실적Sep 30, 2023다음 실적 발표일May 30, 2024주당순이익(EPS)-0.089총이익률-1,367.47%순이익률-2,037.35%부채/자본 비율0%RENE의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/05/04 07:59종가2024/02/05 00:00수익2023/09/30연간 수익2023/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스ReNeuron Group plc는 5명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관David Paul St. JohnsonAllenby Capital LimitedSoo RomanoffEdison Investment ResearchJason McCarthyMaxim Group2명의 분석가 더 보기
공시 • Aug 31ReNeuron Group Admission to Trading on AIM to Be Cancelled with Effect from 2 September 2024ReNeuron Group plc notified of the cancellation of the Company's ordinary shares ("Ordinary Shares") from trading on AIM. Further to the announcement on 2 August 2024 (the "Announcement"), Stephen Cork and Mark Smith of Cork Gully LLP (the "Joint Administrators"), have remained in discussions with the ReNeuron's main creditors to seek to clarify the liabilities of the Company and ascertain the Company's financial solvency in light of its current cash resources. The Joint Administrators anticipate being able to resolve matters such that the Company can exit Administration on a going concern basis in due course. However, this will only occur when the necessary legal documentation has been agreed and the Joint Administrators are working with creditors on this basis. In light of the above, as the Joint Administrators and the Board of ReNeuron no longer consider that there is a realistic possibility that the Company could raise sufficient funds to enable the Company to exit the Administration Process with sufficient working capital that would permit the restoration of trading on AIM on acceptable terms, notwithstanding the ongoing creditor discussions. Therefore,pursuant to Rule 41 of the AIM Rules, and with the ordinary shares of the Company having been suspended for more than six months, the Company's admission to trading on AIM will be cancelled with effect from 7.00 a.m. on 2 September 2024 ("Cancellation").
공시 • Apr 17ReNeuron Group plc Announces Resignation of John Hawkins as Chief Financial Officer, Effect from 7 May 2024ReNeuron Group plc announced that John Hawkins will be stepping down as Chief Financial Officer of the Company with effect from 7 May 2024, in order to pursue other opportunities. Notwithstanding his departure, John will continue to provide support to the Company during the ongoing administration process.
공시 • Jan 30ReNeuron Group plc Provides Group Earnings Guidance for the Second Half and Full Year 2024ReNeuron Group plc provided group earnings guidance for the second half and full year 2024. The Board continues to expect the Group to deliver a stronger performance in the second half than the first.Albeit the weaker regional economic environment means that the Group expects to deliver full year results below market expectations.
Major Estimate Revision • Nov 28Consensus revenue estimates decrease by 28%, EPS upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from UK£910.0k to UK£650.0k. EPS estimate increased from -UK£0.105 to -UK£0.091 per share. Biotechs industry in the United Kingdom expected to see average net income growth of 25% next year. Consensus price target of UK£0.55 unchanged from last update. Share price rose 17% to UK£0.043 over the past week.
New Risk • Nov 09New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: UK£5.1m Forecast net loss in 1 year: UK£1.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£5.3m free cash flow). Revenue is less than US$1m (UK£249k revenue, or US$306k). Market cap is less than US$10m (UK£3.05m market cap, or US$3.74m). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£1.4m net loss next year). Share price has been volatile over the past 3 months (7.7% average weekly change).
공시 • Oct 27ReNeuron Group plc to Report First Half, 2024 Results on Nov 09, 2023ReNeuron Group plc announced that they will report first half, 2024 results on Nov 09, 2023
공시 • Aug 31ReNeuron Group Admission to Trading on AIM to Be Cancelled with Effect from 2 September 2024ReNeuron Group plc notified of the cancellation of the Company's ordinary shares ("Ordinary Shares") from trading on AIM. Further to the announcement on 2 August 2024 (the "Announcement"), Stephen Cork and Mark Smith of Cork Gully LLP (the "Joint Administrators"), have remained in discussions with the ReNeuron's main creditors to seek to clarify the liabilities of the Company and ascertain the Company's financial solvency in light of its current cash resources. The Joint Administrators anticipate being able to resolve matters such that the Company can exit Administration on a going concern basis in due course. However, this will only occur when the necessary legal documentation has been agreed and the Joint Administrators are working with creditors on this basis. In light of the above, as the Joint Administrators and the Board of ReNeuron no longer consider that there is a realistic possibility that the Company could raise sufficient funds to enable the Company to exit the Administration Process with sufficient working capital that would permit the restoration of trading on AIM on acceptable terms, notwithstanding the ongoing creditor discussions. Therefore,pursuant to Rule 41 of the AIM Rules, and with the ordinary shares of the Company having been suspended for more than six months, the Company's admission to trading on AIM will be cancelled with effect from 7.00 a.m. on 2 September 2024 ("Cancellation").
공시 • Apr 17ReNeuron Group plc Announces Resignation of John Hawkins as Chief Financial Officer, Effect from 7 May 2024ReNeuron Group plc announced that John Hawkins will be stepping down as Chief Financial Officer of the Company with effect from 7 May 2024, in order to pursue other opportunities. Notwithstanding his departure, John will continue to provide support to the Company during the ongoing administration process.
공시 • Jan 30ReNeuron Group plc Provides Group Earnings Guidance for the Second Half and Full Year 2024ReNeuron Group plc provided group earnings guidance for the second half and full year 2024. The Board continues to expect the Group to deliver a stronger performance in the second half than the first.Albeit the weaker regional economic environment means that the Group expects to deliver full year results below market expectations.
Major Estimate Revision • Nov 28Consensus revenue estimates decrease by 28%, EPS upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from UK£910.0k to UK£650.0k. EPS estimate increased from -UK£0.105 to -UK£0.091 per share. Biotechs industry in the United Kingdom expected to see average net income growth of 25% next year. Consensus price target of UK£0.55 unchanged from last update. Share price rose 17% to UK£0.043 over the past week.
New Risk • Nov 09New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: UK£5.1m Forecast net loss in 1 year: UK£1.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£5.3m free cash flow). Revenue is less than US$1m (UK£249k revenue, or US$306k). Market cap is less than US$10m (UK£3.05m market cap, or US$3.74m). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£1.4m net loss next year). Share price has been volatile over the past 3 months (7.7% average weekly change).
공시 • Oct 27ReNeuron Group plc to Report First Half, 2024 Results on Nov 09, 2023ReNeuron Group plc announced that they will report first half, 2024 results on Nov 09, 2023
공시 • Jul 25ReNeuron Group plc, Annual General Meeting, Aug 22, 2023ReNeuron Group plc, Annual General Meeting, Aug 22, 2023, at 08:30 Coordinated Universal Time. Location: at the offices of Covington & Burling LLP, Level 54, 22 Bishopsgate London United Kingdom
Major Estimate Revision • Jun 01Consensus EPS estimates upgraded to UK£0.10 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -UK£0.14 to -UK£0.105 per share. Revenue forecast unchanged from UK£906.0k at last update. Biotechs industry in the United Kingdom expected to see average net income growth of 18% next year. Consensus price target down from UK£0.72 to UK£0.59. Share price fell 15% to UK£0.058 over the past week.
Reported Earnings • May 26Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2023 results: UK£0.095 loss per share (improved from UK£0.17 loss in FY 2022). Net loss: UK£5.41m (loss narrowed 44% from FY 2022). Revenue missed analyst estimates by 20%. Earnings per share (EPS) exceeded analyst estimates by 21%.
공시 • May 19ReNeuron Group plc to Report Q4, 2023 Results on May 25, 2023ReNeuron Group plc announced that they will report Q4, 2023 results on May 25, 2023
Board Change • Apr 20High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Independent Non-Executive Director Mike Owen is the most experienced director on the board, commencing their role in 2015. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
공시 • Jan 04+ 1 more updateReNeuron Group plc Appoints Iain Ross as Executive ChairmanReNeuron Group plc announced that Iain Ross, who has been on the Board since July 2021, has been appointed as Executive Chairman and will lead a restructuring of the business, with further announcements to be made in due course. He is an experienced industry executive who has led several successful biotech turnarounds, including more recently that of Redx Pharma plc and Silence Therapeutics plc.
Major Estimate Revision • Dec 09Consensus forecasts updatedThe consensus outlook for 2023 has been updated. 2023 losses forecast to reduce from -UK£0.17 to -UK£0.13 per share. Revenue forecast unchanged from UK£685.3k at last update. Biotechs industry in the United Kingdom expected to see average net income growth of 1.6% next year. Consensus price target of UK£0.79 unchanged from last update. Share price fell 27% to UK£0.11 over the past week.
Reported Earnings • Dec 03First half 2023 earnings released: UK£0.056 loss per share (vs UK£0.092 loss in 1H 2022)First half 2023 results: UK£0.056 loss per share (improved from UK£0.092 loss in 1H 2022). Net loss: UK£3.18m (loss narrowed 39% from 1H 2022). Revenue is forecast to grow 5.2% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Nov 16No longer forecast to breakevenThe 3 analysts covering ReNeuron Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of UK£22.8m in 2024. New consensus forecast suggests the company will make a loss of UK£10.3m in 2024.
Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 independent directors. 4 non-independent directors. Senior Independent Non-Executive Director Barbara Staehelin was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Board Change • Sep 20Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 independent directors. 4 non-independent directors. Senior Independent Non-Executive Director Barbara Staehelin was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Reported Earnings • Aug 18Full year 2022 earnings released: UK£0.17 loss per share (vs UK£0.29 loss in FY 2021)Full year 2022 results: UK£0.17 loss per share (up from UK£0.29 loss in FY 2021). Net loss: UK£9.69m (loss narrowed 15% from FY 2021). Over the next year, revenue is forecast to grow 70%, compared to a 10% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.
분석 기사 • Jul 15We Think ReNeuron Group (LON:RENE) Needs To Drive Business Growth CarefullyWe can readily understand why investors are attracted to unprofitable companies. For example, although...
Price Target Changed • Jul 06Price target decreased to UK£2.22Down from UK£3.58, the current price target is provided by 1 analyst. New target price is 626% above last closing price of UK£0.30. Stock is down 72% over the past year. The company posted a net loss per share of UK£0.17 last year.
Reported Earnings • Jul 04Full year 2022 earnings released: UK£0.17 loss per share (vs UK£0.29 loss in FY 2021)Full year 2022 results: UK£0.17 loss per share (up from UK£0.29 loss in FY 2021). Net loss: UK£9.69m (loss narrowed 15% from FY 2021). Over the next year, revenue is forecast to grow 53,796%, compared to a 160% growth forecast for the pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.
Price Target Changed • Jun 16Price target decreased to UK£2.19Down from UK£3.79, the current price target is an average from 3 analysts. New target price is 584% above last closing price of UK£0.32. Stock is down 73% over the past year. The company posted a net loss per share of UK£0.29 last year.
Price Target Changed • Apr 27Price target decreased to UK£2.04Down from UK£3.02, the current price target is an average from 2 analysts. New target price is 459% above last closing price of UK£0.36. Stock is down 75% over the past year. The company posted a net loss per share of UK£0.29 last year.
분석 기사 • Jan 22We're Keeping An Eye On ReNeuron Group's (LON:RENE) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although...
Price Target Changed • Jan 19Price target decreased to UK£2.04Down from UK£3.00, the current price target is an average from 2 analysts. New target price is 410% above last closing price of UK£0.40. Stock is down 68% over the past year. The company posted a net loss per share of UK£0.29 last year.
Reported Earnings • Dec 02First half 2022 earnings: EPS and revenues miss analyst expectationsFirst half 2022 results: UK£0.092 loss per share (up from UK£0.22 loss in 1H 2021). Net loss: UK£5.23m (loss narrowed 26% from 1H 2021). Revenue missed analyst estimates by 48%. Earnings per share (EPS) also missed analyst estimates by 12%. Earnings per share (EPS) missed analyst estimates by 12%. Over the next year, revenue is forecast to grow 55%, compared to a 17% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 20% per year.
분석 기사 • Oct 12Companies Like ReNeuron Group (LON:RENE) Can Afford To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Reported Earnings • Aug 22Full year 2021 earnings released: UK£0.29 loss per share (vs UK£0.36 loss in FY 2020)Full year 2021 results: Net loss: UK£11.3m (flat on FY 2020). Products in clinical trials Phase II: 2 Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Jul 09Full year 2021 earnings released: UK£0.29 loss per share (vs UK£0.36 loss in FY 2020)Full year 2021 results: Net loss: UK£11.3m (flat on FY 2020). Products in clinical trials Phase II: 2 Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
분석 기사 • Jun 04Will ReNeuron Group (LON:RENE) Spend Its Cash Wisely?We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
분석 기사 • Jan 12Is ReNeuron Group (LON:RENE) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Is New 90 Day High Low • Jan 07New 90-day high: UK£1.11The company is up 18% from its price of UK£0.94 on 09 October 2020. The British market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Dec 16New 90-day low: UK£0.72The company is down 15% from its price of UK£0.85 on 16 September 2020. The British market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period.
Reported Earnings • Nov 26First half 2021 earnings released: UK£0.22 loss per shareFirst half 2021 results: Net loss: UK£7.09m (loss widened 82% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Nov 24New 90-day low: UK£0.78The company is down 23% from its price of UK£1.01 on 26 August 2020. The British market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
분석 기사 • Nov 20Here's What We Learned About The CEO Pay At ReNeuron Group plc (LON:RENE)Olav Hellebo has been the CEO of ReNeuron Group plc (LON:RENE) since 2014, and this article will examine the...
